Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 1
1981 1
1982 1
1983 1
1984 1
1986 1
1987 1
1988 1
1989 1
1990 2
1991 1
1994 2
1995 2
1996 2
1997 1
1998 3
1999 2
2000 2
2001 2
2002 4
2003 2
2004 7
2006 3
2008 1
2009 1
2010 3
2011 4
2012 5
2013 2
2014 4
2015 4
2016 3
2017 9
2018 7
2019 11
2020 11
2021 12
2022 19
2023 14
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Schneider BJ, et al. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724392
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Brahmer JR, et al. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14. J Clin Oncol. 2018. PMID: 29442540 Free PMC article.
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Baxter NN, et al. J Clin Oncol. 2022 Mar 10;40(8):892-910. doi: 10.1200/JCO.21.02538. Epub 2021 Dec 22. J Clin Oncol. 2022. PMID: 34936379
PURPOSE: To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. ...RECOMMENDATIONS: Adjuv …
PURPOSE: To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer. METHODS: ASCO convened an …
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status.
André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ; for the IDEA Steering Committee. André T, et al. Curr Colorectal Cancer Rep. 2013;9(3):261-269. doi: 10.1007/s11888-013-0181-6. Curr Colorectal Cancer Rep. 2013. PMID: 24032000 Free PMC article. Review.
The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration was established to prospectively combine and analyze data from several randomized trials conducted around the world to answer whether a three-month course of oxaliplatin-based adjuvant therapy (FO …
The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration was established to prospectively combine and analyze dat …
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Santomasso BD, et al. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724386
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S, Ramírez-Suástegui C, Li Y, King E, Chudley L, Thomas J, Wood O, von Witzleben A, Jeffrey D, McCann K, Simon H, Mondal M, Wang A, Dicker M, Lopez-Guadamillas E, Chou TF, Dobbs NA, Essame L, Acton G, Kelly F, Halbert G, Sacco JJ, Schache AG, Shaw R, McCaul JA, Paterson C, Davies JH, Brennan PA, Singh RP, Loadman PM, Wilson W, Hackshaw A, Seumois G, Okkenhaug K, Thomas GJ, Jones TM, Ay F, Friberg G, Kronenberg M, Vanhaesebroeck B, Vijayanand P, Ottensmeier CH. Eschweiler S, et al. Nature. 2022 May;605(7911):741-746. doi: 10.1038/s41586-022-04685-2. Epub 2022 May 4. Nature. 2022. PMID: 35508656 Free PMC article. Clinical Trial.
Single-cell RNA-sequencing analysis revealed a PI3Kdeltai-driven loss of tissue-resident colonic ST2 T(reg) cells, accompanied by expansion of pathogenic T helper 17 (T(H)17) and type 17 CD8(+) T (T(C)17) cells, which probably contributed to toxicity; this points towards a …
Single-cell RNA-sequencing analysis revealed a PI3Kdeltai-driven loss of tissue-resident colonic ST2 T(reg) cells, accompanied by exp …
Appendicitis (Nursing).
Lotfollahzadeh S, Lopez RA, Deppen JG, Kendall BA. Lotfollahzadeh S, et al. 2024 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 33760471 Free Books & Documents.
Other theories contend that the appendix acts as a storage vessel for "good" colonic bacteria. Still, others argue that it is a mear developmental remnant and has no real function....
Other theories contend that the appendix acts as a storage vessel for "good" colonic bacteria. Still, others argue that it is a mear …
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
Brown JC, Ma C, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Couture F, Kuebler P, Kumar P, Lewis D, Tan B, Krishnamurthi S, O'Reilly EM, Shields AF, Meyerhardt JA. Brown JC, et al. J Clin Oncol. 2023 Jan 10;41(2):243-254. doi: 10.1200/JCO.22.00171. Epub 2022 Aug 9. J Clin Oncol. 2023. PMID: 35944235 Free PMC article. Clinical Trial.
PURPOSE: To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer. METHODS: We conducted a prospective cohort study nested within a r …
PURPOSE: To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvem …
Targeting Gut Microbial Biofilms-A Key to Hinder Colon Carcinogenesis?
Chew SS, Tan LT, Law JW, Pusparajah P, Goh BH, Ab Mutalib NS, Lee LH. Chew SS, et al. Cancers (Basel). 2020 Aug 13;12(8):2272. doi: 10.3390/cancers12082272. Cancers (Basel). 2020. PMID: 32823729 Free PMC article. Review.
Biofilm results in the redistribution of colonic epithelial cell E-cadherin, increases permeability of the gut and causes a loss of function of the intestinal barrier, all of which enhance intestinal dysbiosis. ...We explore the potential use of natural products, silver na …
Biofilm results in the redistribution of colonic epithelial cell E-cadherin, increases permeability of the gut and causes a loss of f …
Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer.
Cheng E, Caan BJ, Cawthon PM, Evans WJ, Hellerstein MK, Shankaran M, Nyangau E, Campbell KL, Lee C, Binder AM, Meyerhardt JA, Schmitz KH, Cespedes Feliciano EM. Cheng E, et al. Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1373-1381. doi: 10.1158/1055-9965.EPI-23-0227. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37450841 Free PMC article.
CONCLUSIONS: More muscle was associated with improved chemotherapy completion among patients with colon cancer, whereas muscle and adipose tissue were not associated with adverse events. IMPACT: Considering body composition may help personalize dosing for colon canc …
CONCLUSIONS: More muscle was associated with improved chemotherapy completion among patients with colon cancer, whereas muscle and ad …
148 results